TY - JOUR
T1 - Resistance to Some but Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase
AU - Butler, Joshua H.
AU - Baptista, Rodrigo P.
AU - Valenciano, Ana L.
AU - Zhou, Bin
AU - Kissinger, Jessica C.
AU - Tumwebaze, Patrick K.
AU - Rosenthal, Philip J.
AU - Cooper, Roland A.
AU - Yue, Jian Min
AU - Cassera, Maria B.
N1 - Funding Information:
Funding from the National Institutes of Health (AT008088 to M.B.C.; T32-AI060546 to J.H.B.; AI139179 to P.J.R. and R.A.C.), MMV (RD/15/0001 to P.J.R., R.A.C., and P.K.T.), and the National Natural Science Foundation of the P. R. China (21772212 to J.-M.Y.) is gratefully acknowledged. The following reagents were obtained through MR4 as part of the BEI Resources Repository, NIAID, NIH: Plasmodium falciparum Dd2 strain, MRA-150, deposited by D. Walliker and Plasmodium falciparum 3D7 strain, MRA-102, contributed by Daniel J. Carucci. We thank Dr. Dan Goldberg (Washington University) for the gift of PfPARE mutant strains Dd2-2G1-N346Y and 3D7-PARE-S179T. We thank Dr. Drew Etheridge for the gift of anti-Ty1 tag antibody. We also thank Judith I. Okoro and Ryan M. Scales for their assistance with the ex vivo assays.
Publisher Copyright:
© 2020 ACS. All rights reserved.
PY - 2020/11/13
Y1 - 2020/11/13
N2 - Unique lindenane sesquiterpenoid dimers from Chloranthecae spp. were recently identified with promising in vitro antiplasmodial activity and potentially novel mechanisms of action. To gain mechanistic insights to this new class of natural products, in vitro selection of Plasmodium falciparum resistance to the most active antiplasmodial compound, chlorajaponilide C, was explored. In all selected resistant clones, the half-maximal effective concentration (EC50) of chlorajaponilide C increased >250-fold, and whole genome sequencing revealed mutations in the recently discovered P. falciparum prodrug activation and resistance esterase (PfPARE). Chlorajaponilide C was highly potent (mean EC50= 1.6 nM, n = 34) against fresh Ugandan P. falciparum isolates. The analysis of the structure-resistance relationships revealed that in vitro potency of a subset of lindenane sesquiterpenoid dimers was not mediated by PfPARE mutations. Thus, chlorajaponilide C, but not some related compounds, required parasite esterase activity for in vitro potency, and those compounds serve as the foundation for development of potent and selective antimalarials.
AB - Unique lindenane sesquiterpenoid dimers from Chloranthecae spp. were recently identified with promising in vitro antiplasmodial activity and potentially novel mechanisms of action. To gain mechanistic insights to this new class of natural products, in vitro selection of Plasmodium falciparum resistance to the most active antiplasmodial compound, chlorajaponilide C, was explored. In all selected resistant clones, the half-maximal effective concentration (EC50) of chlorajaponilide C increased >250-fold, and whole genome sequencing revealed mutations in the recently discovered P. falciparum prodrug activation and resistance esterase (PfPARE). Chlorajaponilide C was highly potent (mean EC50= 1.6 nM, n = 34) against fresh Ugandan P. falciparum isolates. The analysis of the structure-resistance relationships revealed that in vitro potency of a subset of lindenane sesquiterpenoid dimers was not mediated by PfPARE mutations. Thus, chlorajaponilide C, but not some related compounds, required parasite esterase activity for in vitro potency, and those compounds serve as the foundation for development of potent and selective antimalarials.
KW - Malaria Box
KW - Pathogen Box
KW - PfPARE
KW - Plasmodium
KW - lindenane sesquiterpenoid dimers
KW - structure-resistance relationship study
UR - http://www.scopus.com/inward/record.url?scp=85096152672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096152672&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.0c00487
DO - 10.1021/acsinfecdis.0c00487
M3 - Article
C2 - 32970404
AN - SCOPUS:85096152672
VL - 6
SP - 2994
EP - 3003
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
SN - 2373-8227
IS - 11
ER -